Over the last 7 days, the United States market has experienced a 2.5% drop, yet it remains up by 13% over the past year with earnings forecasted to grow by 14% annually. In this context, identifying high growth tech stocks involves examining companies that demonstrate strong potential for expansion and innovation amidst these dynamic market conditions.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 234 stocks from our US High Growth Tech and AI Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

TG Therapeutics

Simply Wall St Growth Rating: ★★★★★★

Overview: TG Therapeutics, Inc. is a commercial stage biopharmaceutical company dedicated to acquiring, developing, and commercializing innovative treatments for B-cell mediated diseases globally, with a market cap of $4.32 billion.

Operations: TG Therapeutics focuses on developing and commercializing novel treatments for B-cell mediated diseases both in the U.S. and internationally. The company operates as a commercial stage biopharmaceutical entity, leveraging its expertise in acquiring innovative therapies to address unmet medical needs.

TG Therapeutics has demonstrated a robust performance with a significant turnaround in its financial metrics, as evidenced by its latest quarterly results where revenue surged to $108.19 million from $43.97 million year-over-year and net income reached $23.33 million, reversing a previous loss of $14.42 million. This growth trajectory is underscored by the company's aggressive R&D investments aimed at enhancing its product offerings, particularly BRIUMVI, which is projected to generate substantial U.S. net product revenue of approximately $525 million in 2025 out of total expected global revenues of $540 million. The firm's strategic focus on innovative treatments for multiple sclerosis positions it well within the biotech sector, where it has outpaced industry growth rates with an earnings increase of 84.5% over the past year compared to the industry’s 38.5%.

• Dive into the specifics of TG Therapeutics here with our thorough health report.

• Review our historical performance report to gain insights into TG Therapeutics''s past performance.

Exelixis

Simply Wall St Growth Rating: ★★★★★☆

Overview: Exelixis, Inc. is an oncology company dedicated to discovering, developing, and commercializing new medicines for difficult-to-treat cancers in the United States, with a market cap of $10.83 billion.

Operations: Exelixis generates revenue primarily from the discovery, development, and commercialization of new medicines for difficult-to-treat cancers, amounting to $2.17 billion. The company's focus on oncology positions it within a specialized segment of the pharmaceutical industry.

Exelixis, Inc. recently announced a robust share repurchase program, committing to buy back up to $500 million of its stock by the end of 2025, signaling strong confidence in its financial health and future prospects. This move follows a year of significant financial achievements for Exelixis, with annual revenue reaching $2.17 billion, marking an 18.5% increase from the previous year's $1.83 billion. The company's net income more than doubled to $521 million from $208 million, reflecting not only improved operational efficiencies but also successful outcomes in critical clinical trials such as the CheckMate -9ER study which demonstrated long-term efficacy benefits of CABOMETYX in combination with Opdivo for renal cell carcinoma. These results underscore Exelixis' strategic focus on oncology and innovative cancer treatments, positioning it well within the high-stakes biopharmaceutical sector amidst growing competition and evolving treatment paradigms.

• Delve into the full analysis health report here for a deeper understanding of Exelixis.

• Explore historical data to track Exelixis' performance over time in our Past section.

Waystar Holding

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Waystar Holding Corp. provides a cloud-based software solution for healthcare payments and has a market cap of $7.33 billion.

Operations: The company generates revenue through its healthcare software segment, which brought in $943.55 million.

Waystar Holding's recent launch of Auth Accelerate, an advanced automation tool for streamlining prior authorizations, marks a significant stride in tackling healthcare's administrative complexities. This innovation not only enhances operational efficiencies by reducing submission times by 70% and increasing auto-approval rates to 85% but also significantly cuts the average wait time for payer approval from days to less than one day. Coupled with a robust financial performance that saw a revenue jump from $791 million to $943.55 million year-over-year and a turnaround to $19.08 million net income from a previous net loss, Waystar is positioning itself as a pivotal player in healthcare tech by directly addressing industry-wide inefficiencies through technological advancement.

• Take a closer look at Waystar Holding's potential here in our health report.

• Gain insights into Waystar Holding's past trends and performance with our Past report.

Turning Ideas Into Actions

• Discover the full array of 234 US High Growth Tech and AI Stocks right here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqCM:TGTX NasdaqGS:EXEL and NasdaqGS:WAY.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com